PETITION

PETITION

Share this post

PETITION
PETITION
💥New Chapter 11 Bankruptcy Filing - DMK Pharmaceuticals Corporation ($DMK)💥
Copy link
Facebook
Email
Notes
More

💥New Chapter 11 Bankruptcy Filing - DMK Pharmaceuticals Corporation ($DMK)💥

Pharma company seeks to negotiate with DOJ and creditors over a plan.

Feb 03, 2024
∙ Paid
1

Share this post

PETITION
PETITION
💥New Chapter 11 Bankruptcy Filing - DMK Pharmaceuticals Corporation ($DMK)💥
Copy link
Facebook
Email
Notes
More
Share

On February 2, 2024, NJ-based DMK Pharmaceuticals Corporation (OTCMKTS: $DMKPG) and five affiliates (together, the “debtors”) filed chapter 11 bankruptcy cases in the District of Delaware (Judge Walrath). DMK represents a family of pharmaceutical companies owning a portfolio of treatments, including five therapies, two of which have obtained approval from the FDA and are commercially saleable. The two commercial therapies include (i) Symjempi and (ii) Zimhi. The former is a transportable injection of epinephrine (very similar to Epipen) indicated for the emergency treatment of allergic reactions; the latter, which was acquired as part of a mid-’23 — and now controversial (see below) — merger, is an opioid antagonist for the emergency treatment of opioid overdoses and fentanyl poisonings. 

This post is for paid subscribers

Already a paid subscriber? Sign in
© 2025 Petition LLC
Publisher Privacy ∙ Publisher Terms
Substack
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share

Copy link
Facebook
Email
Notes
More